Please login to the form below

Not currently logged in
Email:
Password:

commercialisation

This page shows the latest commercialisation news and features for those working in and with pharma, biotech and healthcare.

Moderna inks R&D agreements with Vertex and Chiesi

Moderna inks R&D agreements with Vertex and Chiesi

therapies to be formulated into LNPs, as well as the preclinical and clinical development and commercialisation efforts of any potential candidates.

Latest news

More from news
Approximately 0 fully matching, plus 492 partially matching documents found.

Latest Intelligence

  • The global antibiotic crisis: a 2020 perspective The global antibiotic crisis: a 2020 perspective

    The average new drug in other therapeutic areas passes through four or five owners on its journey from discovery to commercialisation – from universities and research institutes, through small and medium-sized

  • Mapping the patient journey and minding the gap Mapping the patient journey and minding the gap

    The good news is we’re seeing more and more patients invited into discussions, with companies establishing patient panels and advisory boards to inform all aspects of drug development and commercialisation. ... evolving. Whether you’re Facebook, Uber

  • New strategic blueprint: the new first questions New strategic blueprint: the new first questions

    By Thunicia Moodley. The first questions around commercialisation now start with value and access. ... As we enter a challenging new era of commercialisation, life sciences leaders are changing the strategic playbook, starting with the very first

  • A market-adapted agile approach to launch excellence A market-adapted agile approach to launch excellence

    and differing lead launch markets. Recommendation: think differently by identifying market launch archetypes for launch readiness, prioritising launch activities stringently and developing tailored commercialisation strategies.

  • It started with a miss It started with a miss

    The traditional approaches to launching a product still tend to sit in the commercial function,” said Chuck Stevens, Vice President and Global Head of Access, Commercialisation &Communications at ICON plc.

More from intelligence
Approximately 2 fully matching, plus 125 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 122 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 5 fully matching, plus 31 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics